Illumina Sees Strong Clinical Demand, but Research Recovery Remains in Question

Illumina (NASDAQ:ILMN) is seeing strong demand for its sequencing instruments from clinical customers, while remaining cautious about a recovery in research spending, Chief Financial Officer Ankur Dhingra said at a company news event.

Dhingra said the company was making progress toward a goal, laid out in 2024, of returning to high-single-digit growth. He described growth during 2026 as steadily in the mid-single digits across the quarters and in the company’s fourth-quarter guidance.

Illumina reported a 25% operating margin in the third quarter and was guiding to approximately 25% for the fourth quarter, he said. That would put the second half at roughly 25%, a milestone toward the company’s target of 500 basis points of margin expansion in its core businesses.

Clinical demand supports instrument placements

Dhingra said clinical customers, particularly in the United States, have driven much of the upside in demand. Illumina placed more instruments over the past four quarters than it did during the first year of the NovaSeq X launch, he said.

A larger installed base gives the company more confidence in future consumables growth, though clinical customers typically take longer than research customers to reach peak consumables usage. They must validate instruments, and usage increases as tests or clinical trials ramp up, Dhingra said.

Asked whether U.S. clinical consumables growth above 20% was sustainable, Dhingra pointed to demand for therapy selection and growth opportunities in minimal residual disease and multicancer early detection. He said Illumina could sustain growth consistent with its customers’ ambitions if those customers continue to execute their plans.

Outside the United States, Dhingra said minimal residual disease and early cancer detection have not yet provided much of a tailwind. He said recent reimbursement changes in Germany had a relatively small impact on Illumina’s business.

Conversion to the newer high-throughput platform stood at 78% at the end of the third quarter, Dhingra said, and was approaching the 80% to 85% range over the next few quarters. Beyond that level, he expects a long tail of customers who may not see an immediate economic reason to move existing tests to the newer technology.

AI and multiomics opportunities

Illumina is in discussions with artificial intelligence companies about their data needs, but Dhingra said the range of potential outcomes remains wide. Smaller AI companies are buying instruments, commissioning data generation or purchasing datasets, he said, although the revenue is not yet material to Illumina’s overall business.

The company expects new products to contribute an additional one to two percentage points of growth in its 2027 framework, with BioInsight and AI among the larger contributors, Dhingra said.

He also expects Illumina to work more closely with pharmaceutical customers, citing both AI and the breadth of its multiomics portfolio. The company has been building its Billion Cell Atlas with input from pharmaceutical customers and has made money on it through agreements with them, he said.

Research remains cautious; China grows

Illumina’s research business has seen slower rates of decline, and its dollar revenue has improved sequentially for three quarters, Dhingra said. Some of that increase reflects normal seasonality, however, and he said the company was not ready to call a turn in the market.

Customers have reported improved funding and activity but remain uncertain about the outlook, he said. Illumina wants to see sustained recovery and customers making longer-term commitments to lab capacity or larger projects before declaring a market turn.

In China, revenue grew 5% in the third quarter, Dhingra said. Illumina is assembling more instruments locally and continuing to supply its installed base with consumables. He said the company would keep supporting customers while the issue of its inclusion on China’s UEL remains a national-level discussion.

About Illumina (NASDAQ:ILMN)

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.